List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for the given year is not complete until April of the following year. Annual Reports data is a snapshot of agency reported information for that year and hence might look different from the live data in the Awards Information charts.

  1. A Novel Polymeric Trileaflet Heart Valve Prosthesis

    SBC: ABIOMED, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The development of a durable, hemocompatible valve prosthesis is the long-term objective of this proposal. While heart valve prostheses have been used successfully since 1960, 10-year survival rates still range from

    SBIR Phase I 2004 Department of Health and Human Services
  2. Fail-safe TET system for implanted life support devices

    SBC: ABIOMED, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Cardiac assist devices are increasingly being used for long term support. As patient survival times increase substantially, long-term management of the patients will increasingly play a role in suitability of these

    SBIR Phase I 2004 Department of Health and Human Services
  3. A Smart Polymer for Destination Cardiac Assist Devices

    SBC: ABIOMED, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Cardiac assist devices are increasingly being used for long term support. As patient survival times increase substantially, device wear-out will increasingly play a role in the clinical management of patients with l

    SBIR Phase I 2004 Department of Health and Human Services
  4. Three Dimensional ECM Scaffolds for Tissue Engineering

    SBC: ACELL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This Phase I SBIR application seeks support to develop a three dimensional acellular scaffold composed of particulate extracellular matrix (ECM). Products composed of the two dimensional (sheet form) of ECM der

    SBIR Phase I 2004 Department of Health and Human Services
  5. Novel A2A Adenosine Agonists in Vascular Protection

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is a phase II SBIR proposal to develop a new drug eluting stent to prevent restenosis. It is a 3-way collaboration between Adenosine Therapeutics, LLC, Setagon, Inc., and the University of Virginia. The work described here will be done at Adenosine Therapeutics (compound synthesis and pharmacokinetics) and the University of Virginia (Stent studies in pigs) ...

    STTR Phase II 2004 Department of Health and Human Services
  6. Antagonists of A2B Receptors Improve Insulin Sensitivity

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is a phase II SBIR grant to develop a new therapy for the treatment of type II diabetes. Adenosine Therapeutics, LLC (ATL) is a biotechnology company started in Charlottesville, Virginia in 1999. ATL owns patents

    SBIR Phase II 2004 Department of Health and Human Services
  7. A2A Adenosine Receptor Agonist for the Treatment of IBD

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Adenosine Therapeutics, LLC (ATL) is a biotechnology company started in Charlottesville, Virginia in 1999. ATL owns patents on the formulation and use of a family of potent and highly selective agonists of A2A adenosin

    SBIR Phase I 2004 Department of Health and Human Services
  8. New Agents That Inhibit Fatty Acid Accumulation

    SBC: ADIPOGENIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Existing treatments for obesity are only modestly effective. The mission of AdipoGenix, Inc. is

    SBIR Phase II 2004 Department of Health and Human Services
  9. Small Molecule Blockers of B. anthracis Toxin

    SBC: Innovative Biologics Inc.            Topic: N/A

    DESCRIPTION (provided by investigator): Results from our SBIR Phase I project demonstrated that beta-cyclodextrin derivatives designed to block the trans-membrane channel formed by B. anthracis protective antigen (PA) can inhibit the cytotoxic effects

    SBIR Phase II 2004 Department of Health and Human Services
  10. Impedance based knee simulation control

    SBC: Advanced Mechanical Technology, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Over 299,000 total knee replacement procedures were conducted in 2002 with projections to 474,000 by 2030. It is estimated that the annual cost of TKR exceeds $6 billion in the US. Despite the success of TKR revisi

    SBIR Phase I 2004 Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government